Novartis AG announced it is signing a new agreement with German biotech firm MorphoSys AG, extending their alliance for 10 more years. The potential $1 billion collaborative deal will concentrate on developing antibody-based biological drugs for a wide range of diseases, and also allows Novartis exclusive access to MorphoSys's human antibody libraries.

Related Summaries